Sign up to save your podcasts
Or
Share Targeting alpha synuclein in early Parkinson's disease. Clinical trials and future perspectives
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Targeting alpha synuclein in early Parkinson's disease. Clinical trials and future perspectives
Two clinical trials with antibodies targeting alpha synuclein in early Parkinson's disease have been published in the New England Journal of Medicine. Anthony Lang and Gennaro Pagano, the first authors of the articles share the results and discuss the possible future perspectives with the MDS Podcast editor, Michele Matarazzo.
Read the prasinezumab article.
Read the cinpanemab article.
View all episodes
By International Parkinson and Movement Disorder Society
4.8
88 ratings
Two clinical trials with antibodies targeting alpha synuclein in early Parkinson's disease have been published in the New England Journal of Medicine. Anthony Lang and Gennaro Pagano, the first authors of the articles share the results and discuss the possible future perspectives with the MDS Podcast editor, Michele Matarazzo.
Read the prasinezumab article.
Read the cinpanemab article.
More shows like MDS Podcast
View all
Conversations
857 Listeners
Neurology® Podcast
286 Listeners
EMCrit FOAM Feed
1,868 Listeners
NEJM This Week
319 Listeners
Practical Neurology Podcast
36 Listeners
The Curbsiders Internal Medicine Podcast
3,325 Listeners
JAMA Medical News
85 Listeners
BMJ Best Practice Podcast
32 Listeners
Core IM | Internal Medicine Podcast
1,094 Listeners
Navigating Neuropsychology
341 Listeners
The Clinical Problem Solvers
509 Listeners
Neurology Minute
131 Listeners
Harrison's PodClass: Internal Medicine Cases and Board Prep
321 Listeners
eanCast: Weekly Neurology
0 Listeners
Continuum Audio
78 Listeners